Nihon Kohden (OTCMKTS:NHNKY) Stock Rating Lowered by UBS Group

Nihon Kohden (OTCMKTS:NHNKY) was downgraded by research analysts at UBS Group from a “strong-buy” rating to a “hold” rating in a research note issued on Wednesday,Zacks.com reports.

Separately, Zacks Research upgraded Nihon Kohden to a “hold” rating in a report on Monday, April 27th. Two equities research analysts have rated the stock with a Hold rating, According to MarketBeat, the stock presently has an average rating of “Hold”.

Nihon Kohden Stock Performance

NHNKY stock opened at $9.23 on Wednesday. Nihon Kohden has a 52 week low of $8.12 and a 52 week high of $14.21. The firm’s fifty day moving average is $9.17 and its 200 day moving average is $9.68. The firm has a market cap of $1.55 billion, a P/E ratio of 16.77 and a beta of 0.37.

Nihon Kohden (OTCMKTS:NHNKY) last posted its quarterly earnings results on Thursday, August 6th. The company reported ($0.03) earnings per share for the quarter, missing the consensus estimate of $0.06 by ($0.09). Nihon Kohden had a return on equity of 9.08% and a net margin of 5.90%.The business had revenue of $297.47 million during the quarter, compared to the consensus estimate of $299.98 million. As a group, analysts forecast that Nihon Kohden will post 0.6 EPS for the current year.

Nihon Kohden Company Profile

Nihon Kohden Corporation is a Tokyo-based manufacturer of medical electronic equipment, founded in 1951. The company has built a reputation for innovation in patient monitoring and diagnostic systems, developing one of Japan’s earliest electrocardiogram (ECG) machines and pioneering transistor-based oscilloscopes for clinical use. Over the decades, Nihon Kohden has expanded its product portfolio to address a wide range of healthcare needs, from emergency response to intensive care and neurology.

The company’s core offerings include patient monitors, ECG and electroencephalograph (EEG) devices, defibrillators, infusion pumps, and neuromonitoring systems.